|
|
Article: OrthoLogic announces FDA approval of an IDE for another SpinaLogic 1000 clinical study; New study to investigate effectiveness on failed spinal fusion surgery.
- Article from:
- Business Wire
- Article date:
- September 15, 1995
CopyrightCOPYRIGHT 1995 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PHOENIX--(BUSINESS WIRE)--Sept. 15, 1995--OrthoLogic (NASDAQ:OLGC) Friday announced that it has received approval of an Investigational Device Exemption (IDE) from the FDA to initiate a second study for the SpinaLogic(R) 1000 Bone Growth Stimulator.
This new study will investigate the safety and effectiveness of the SpinaLogic(R) 1000 as a nonoperative treatment for failed spinal fusion surgery, where a minimum of nine months have elapsed since surgery.
The SpinaLogic(R) 1000, which in this study will be prescribed in lieu of additional surgery, is a noninvasive, easy to use, portable, battery operated, low-energy magnetic field bone growth stimulator that ...